Helaine Fingold Quoted in “Trump Regulation Freeze Could Put Chill on Medicare Advantage Funding”

Helaine I. Fingold, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Baltimore office, was quoted in Health Payer Specialist, in “Trump Regulation Freeze Could Put Chill on Medicare Advantage Funding,” by Gale Scott. (Read the full version – subscription required.)

Following is an excerpt:

But according to an analysis by the Epstein Becker Green law firm, the Trump regulatory freeze could potentially affect any rule or guidance that has not yet taken effect–even those that face statutory deadlines for enactment.

At the firm's Baltimore office, partner Helaine Fingold said the administration still has time to make regulatory changes affecting MA, even after the April 7 deadline for announcing rates.

"There's not a timetable for the rule to be finalized, and there's an opportunity for delay and to take as much time as they need," she said. "To the extent that things are still undecided, the payers don't know what the rules are going to be, what the benefit packages will be, and what plans will look like," she said.

"The longer it's up in the air, the more challenging it will be for the plans," she added.